What Generation of Cephalosporin Is Cefepime?

Cefepime is a fourth-generation cephalosporin, a classification it earned in the 1990s because it combined the gram-positive coverage of older cephalosporins like cefotaxime with the gram-negative reach of ceftazidime, while also remaining active against many bacteria that had learned to resist both of those predecessors.¹ That dual-spectrum profile, plus structural features that help it slip past bacterial defenses, is what separates it from the third-generation drugs that came before it. The “generation” label sounds simple, but a surprising amount of chemistry and clinical decision-making sits behind it.

What the Generations Actually Mean

Cephalosporins are grouped into generations based on their spectrum of antibacterial activity, not strictly on the year they were developed. First-generation drugs work well against common gram-positive bacteria like staphylococci and streptococci but have limited gram-negative coverage. Second-generation agents gained some gram-negative reach. Third-generation cephalosporins like ceftriaxone and ceftazidime pushed gram-negative coverage much further, becoming go-to drugs for serious hospital infections, but they often traded away some gram-positive potency in the process.

Cefepime earned its fourth-generation label precisely because it refused to make that trade-off. Its gram-positive spectrum stayed comparable to cefotaxime (a third-generation drug known for solid gram-positive activity), while its gram-negative spectrum matched ceftazidime (the third-generation workhorse against tough gram-negatives like Pseudomonas aeruginosa). On top of that, many organisms that had developed resistance to cefotaxime or ceftazidime remained susceptible to cefepime.² That combination of breadth and resistance-dodging is the defining feature of the fourth generation.

Why Cefepime Gets Through Bacterial Walls

One of the cleverer aspects of cefepime’s design is its electrical charge. The molecule is zwitterionic, meaning it carries both a positive and a negative charge at the same time, giving it a net charge of roughly zero. That matters because gram-negative bacteria have an outer membrane studded with channel proteins called porins, and the charge of an antibiotic determines how easily it can pass through those channels.

Research measuring how fast different cephalosporins move through the two main porin types in Enterobacterales (OmpF and OmpC) found that cefepime passed through with essentially unhindered diffusion, while third-generation drugs like ceftazidime faced a sizable barrier that slowed them down.³ That rapid entry means cefepime reaches its targets inside the bacterium before the cell’s defense enzymes can chew it up. Mutations in specific charged residues of the OmpF porin channel can disrupt cefepime’s passage, confirming that the drug’s ability to navigate the electrostatic environment of the channel is central to its effectiveness.⁴

How It Kills Bacteria Once Inside

Like all cephalosporins, cefepime works by binding to penicillin-binding proteins (PBPs), which are enzymes bacteria need to build and maintain their cell walls. Block these enzymes, and the bacterial cell wall weakens and eventually ruptures. But cefepime’s binding profile is distinctive. In E. coli, it shows strong affinity for PBP 3, the enzyme most directly involved in cell division, with very low concentrations needed to shut it down. What sets cefepime apart from related fourth-generation compounds like cefpirome and cefaclidine is its unusually tight binding to PBP 2, with roughly a 20-fold advantage over those other drugs for that specific target.⁵

This superior PBP 2 binding traces to a specific piece of the cefepime molecule: a quaternized N-methyl pyrrolidine group attached at one end of its core structure. Swapping in different chemical groups at the same position, as in cefpirome or cefaclidine, drops PBP 2 affinity dramatically.⁶ Hitting two different PBP targets gives cefepime a more lethal one-two punch: PBP 3 inhibition stops bacteria from dividing, and PBP 2 inhibition destabilizes cell shape. Against Pseudomonas aeruginosa, all these fourth-generation drugs bind PBP 3 extremely well but bind PBP 2 poorly, which partly explains why Pseudomonas can be a tougher target.⁷

Where Cefepime Fits in Clinical Practice

Cefepime’s broad spectrum has made it a standard choice for several serious infection scenarios, especially in hospitals. One of its most established roles is empiric therapy for febrile neutropenia, the dangerous combination of fever and a collapsed white blood cell count that often follows chemotherapy. In trials, cefepime monotherapy successfully controlled roughly 83% of febrile neutropenia episodes without needing additional antibiotics.⁸ Head-to-head comparisons with other broad-spectrum agents have consistently found comparable effectiveness: cefepime performed similarly to piperacillin/tazobactam in pediatric cancer patients with febrile neutropenia, and similarly to the carbapenem imipenem-cilastatin in adult hematological malignancy patients.⁹¹⁰

For community-acquired pneumonia requiring hospitalization, cefepime has shown cure-or-improvement rates around 95%, statistically equivalent to ceftriaxone, the third-generation drug most commonly used for that indication.¹¹ In treating other serious bacterial infections, a randomized trial comparing cefepime to ceftazidime found satisfactory clinical response rates of 86% and 77% respectively, with cefepime carrying the practical advantage of twice-daily dosing instead of three times daily.¹²

Gram-Positive Coverage and the SENTRY Data

A common misconception is that fourth-generation cephalosporins are purely gram-negative specialists. Surveillance data from over 12,000 staphylococcal and streptococcal isolates across North America showed that cefepime maintained strong activity against oxacillin-susceptible staphylococci, with susceptibility rates above 98%, outperforming ceftazidime’s 93% in the same analysis. Against Streptococcus pneumoniae, cefepime and ceftriaxone both remained highly active against penicillin-susceptible and penicillin-intermediate strains, though activity dipped to around 80-82% against fully penicillin-resistant isolates.¹³ That gram-positive activity is part of what distinguishes cefepime from ceftazidime, which sacrificed staphylococcal coverage for its anti-Pseudomonal strength.

Worth noting: cefepime has no useful activity against methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus species. Those gaps are not unique to cefepime; they apply across all cephalosporins currently available.

The Beta-Lactamase Problem

The biggest threat to cefepime’s usefulness is beta-lactamases, enzymes that bacteria produce to break the core structure of cephalosporins before they can reach their targets. Cefepime was designed with some built-in resistance to these enzymes: its zwitterionic structure and rapid porin penetration mean it can often reach PBPs before AmpC beta-lactamases, produced by organisms like Enterobacter and Citrobacter, can destroy it.

Extended-spectrum beta-lactamases (ESBLs) are a more serious problem. A study of 280 ESBL-producing Enterobacterales from a Brazilian hospital found that only about 12% were susceptible to cefepime by standard criteria.¹⁴ That finding reflects a broader clinical reality: once a bacterium produces ESBLs, cefepime alone is often insufficient. This is exactly the kind of resistance gap that newer combination therapies are trying to close.

New Combinations Extending Cefepime’s Reach

Rather than abandon cefepime in the face of rising resistance, researchers have paired it with novel beta-lactamase inhibitors that shield the drug from enzymatic destruction. Two combinations are at the forefront.

Cefepime-taniborbactam pairs the drug with a boronic-acid inhibitor that blocks both serine beta-lactamases and metallo-beta-lactamases, a feat that older inhibitors cannot manage. In a global surveillance program testing over 20,000 Enterobacterales isolates, the addition of taniborbactam dropped the concentration needed to inhibit 90% of strains by more than 64-fold compared to cefepime alone, and 99.5% of all Enterobacterales were susceptible to the combination. Against roughly 8,000 Pseudomonas aeruginosa isolates, 96.5% were susceptible, including most carbapenem-resistant strains carrying the most feared resistance enzymes.¹⁵

Cefepime-enmetazobactam takes a different approach. Enmetazobactam targets class A beta-lactamases, which includes the KPC and CTX-M families responsible for much of the ESBL crisis. Pairing it with cefepime boosted susceptibility among ESBL-producing Enterobacterales from roughly 2% to 98%. The trade-off is that enmetazobactam does not cover metallo-beta-lactamases or OXA-type enzymes, so the combination has blind spots against certain carbapenem-resistant organisms and against Acinetobacter baumannii.¹⁶ The two combinations are complementary rather than redundant: taniborbactam covers a wider enzyme spectrum including metallo-beta-lactamases, while enmetazobactam is focused more narrowly on the class A enzymes that cause the most common ESBL infections.

How the Body Handles Cefepime

Cefepime is given intravenously or intramuscularly; it is not absorbed well enough orally to be useful. Once in the bloodstream, it has a half-life of about two hours in adults with normal kidneys.¹⁷ The drug distributes broadly into tissues and body fluids, and the body eliminates it primarily by filtering it through the kidneys unchanged. Over 80% of a dose is recovered intact in the urine, and the renal clearance values suggest glomerular filtration is the main excretion route, with minimal involvement of the liver.¹⁸

Because the kidneys do nearly all the work, kidney impairment changes the picture substantially. As kidney function declines, cefepime’s half-life lengthens proportionally, and urinary recovery drops significantly once creatinine clearance falls below about 30 mL per minute.¹⁹ This renal dependence is the root cause of the drug’s most worrisome side effect.

Neurotoxicity and Who Is Most at Risk

Cefepime can cross the blood-brain barrier. In patients whose kidneys cannot clear the drug efficiently, blood and brain concentrations climb, and the drug begins to interfere with a key inhibitory neurotransmitter called GABA. Specifically, cefepime acts as a competitive antagonist at GABA-A receptors, blocking the normal inhibitory signaling that keeps neuronal firing in check.²⁰ The result can be confusion, altered consciousness, myoclonus (involuntary muscle jerking), and in severe cases, seizures or coma.

A systematic review of cefepime-induced neurotoxicity found that benzodiazepines, which enhance GABA activity, were used as a treatment intervention in dozens of reported cases, consistent with the proposed mechanism of GABA blockade.²¹ The most important step, though, is stopping the drug or adjusting the dose. Symptoms typically resolve once cefepime levels fall.

Older adults and patients with kidney dysfunction are at the highest risk, and many neurotoxicity cases have occurred with standard dosing in patients whose kidney function was not adequately accounted for. Therapeutic drug monitoring, measuring actual cefepime levels in the blood, can catch dangerous accumulation early and has been recommended as a tool to improve safety in hospitalized patients with unstable renal function.²²

Getting the Dose Right in Critically Ill Patients

Cefepime, like other cephalosporins, kills bacteria in a time-dependent fashion. The critical parameter is not how high the peak concentration goes but rather how long the free (unbound) drug concentration stays above the minimum inhibitory concentration for the pathogen. Various studies have used slightly different targets: some define success as the free drug exceeding the MIC for at least 60% of the dosing interval, while others push for 100% of the interval above the MIC or even 100% above four times the MIC when treating critically ill patients.²³²⁴

The tension is obvious: pushing for higher, longer drug exposure improves the chance of bacterial killing but also raises the risk of neurotoxicity, especially in patients with fluctuating kidney function. Extended infusion strategies, where the same total dose is dripped in over three or four hours rather than bolused in 30 minutes, help maintain drug levels above the MIC for longer without creating dangerously high peaks. Studies in critically ill patients have explored these regimens specifically to thread the needle between efficacy and toxicity.²⁵

Cefepime in Newborns and Infants

Neonates handle cefepime differently from adults, and the differences are large enough to require dedicated dosing strategies. In premature and term newborns, cefepime clearance is roughly 40% of what it is in older infants, because the kidneys are still maturing.²⁶ The slower clearance means the drug sticks around longer, leading to higher trough levels. The volume of distribution is also larger in the most premature infants (those born before 30 weeks of gestation), reflecting higher total body water as a proportion of body weight.

Population pharmacokinetic modeling in neonates has suggested that a dose of 30 mg per kilogram every 12 hours for infants under two weeks of age provides drug exposure equivalent to or greater than the standard 50 mg per kilogram every 8 hours used in older children.²⁷ This is a useful example of how the same drug, at the same “generation” classification, requires fundamentally different handling depending on the patient. Serum creatinine in the first days of life partly reflects maternal creatinine, so adjusting doses by kidney function markers in neonates is trickier than in adults, where creatinine more reliably predicts drug clearance.

Is There a Fifth Generation?

The generation system was not designed to go on forever, and it has gotten fuzzy past the fourth. Ceftaroline and ceftobiprole are sometimes called fifth-generation cephalosporins because they have activity against MRSA, a gap that no first- through fourth-generation cephalosporin can fill. But the label is informal and not universally accepted; some microbiologists prefer “advanced-generation” or simply describe them by spectrum. Cefepime remains firmly in the fourth-generation slot, and its clinical profile has not been rendered obsolete by these newer agents. Where MRSA is not a concern, cefepime’s combination of anti-Pseudomonal and gram-positive coverage keeps it competitive, especially when paired with one of the new beta-lactamase inhibitors.

The generation system itself is more of a clinical shorthand than a rigorous taxonomy. It groups drugs that share a rough spectrum, but within any generation there are real differences in how individual agents handle specific pathogens, how they behave in the body, and which resistance mechanisms they can withstand. Cefepime’s position as a fourth-generation drug tells you it covers more ground than third-generation agents, but the details of why, from its zwitterionic charge to its PBP binding profile to its renal elimination, are what actually determine whether it is the right choice for a given patient and a given infection.